+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Glucagon Like Peptide-1 Agonists Market - Global Forecast 2026-2032- Product Image
Glucagon Like Peptide-1 Agonists Market - Global Forecast 2026-2032- Product Image
Sale

Glucagon Like Peptide-1 Agonists Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6121849
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Glucagon Like Peptide-1 Agonists Market is projected to reach USD 14.58 Billion in 2026. It is expected to continue growing at a CAGR of 9.56%, reaching USD 25.43 Billion by 2032.

Introduction to Glucagon-Like Peptide-1 Agonists

Glucagon-like peptide-1 (GLP-1) agonists are medicines that activate receptors involved in glucose regulation, appetite control, and gastrointestinal signaling. They are used primarily in type 2 diabetes and, for selected products and patients, chronic weight management. Their clinical relevance reflects the growing need to improve glycemic control, address obesity-related complications, and support treatment strategies that combine medication with nutrition and physical activity. Access, prescribing practice, reimbursement, safety monitoring, and approved indications differ substantially across health systems.

Transformative Shifts in Diabetes and Obesity Care

Care is shifting from isolated glucose reduction toward integrated cardiometabolic risk management. Clinicians increasingly evaluate weight, cardiovascular risk, kidney health, treatment adherence, and patient preferences alongside glycated hemoglobin. Longer-acting dosing options, more structured obesity services, and broader use of digital follow-up are changing care pathways. At the same time, gastrointestinal tolerability, contraindications, discontinuation risk, supply resilience, and equitable access remain important implementation challenges. Evidence-based patient selection and continued monitoring are therefore central to responsible adoption.

How Artificial Intelligence Is Reshaping GLP-1 Agonist Care

Artificial intelligence can support GLP-1 agonist care by identifying patients who may benefit from treatment, detecting adherence or discontinuation signals, and helping clinicians interpret longitudinal glucose, weight, and comorbidity data. Predictive tools may also assist with adverse-event monitoring, individualized titration support, and demand planning. However, these applications require clinically validated datasets, transparent performance standards, privacy safeguards, and human oversight. AI should augment-not replace-prescriber judgment, shared decision-making, pharmacovigilance, and assessment of social determinants that influence treatment access and persistence.

Regional Insights Across Six Healthcare Landscapes

North America is characterized by strong clinical awareness, significant demand for diabetes and obesity services, and ongoing debate over affordability, coverage, and supply. Europe emphasizes guideline-based care, health-technology assessment, coordinated reimbursement, and safety monitoring. Asia-Pacific combines substantial diabetes burdens with varied regulatory systems, income levels, and access pathways. Latin America faces uneven availability, out-of-pocket pressure, and growing interest in obesity management. The Middle East is expanding chronic-disease programs while addressing prevention and specialist capacity. Africa requires solutions suited to constrained health infrastructure, diagnosis gaps, affordability challenges, and reliable medicine distribution.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN members present diverse regulatory environments and healthcare resources, making regional cooperation, clinician education, and supply-chain coordination valuable. BRICS economies span large and varied patient populations, with priorities that include domestic manufacturing capacity, affordability, and broader chronic-disease access. The European Union benefits from shared regulatory structures while retaining national differences in reimbursement and prescribing. G7 systems generally have advanced clinical infrastructure but continue to address coverage, budget impact, and equitable access. GCC countries are strengthening chronic-disease prevention and specialist services, while NATO membership itself is not a healthcare market category; relevant implications are indirect, including resilience of medical supply chains and continuity planning across member health systems.

Country Insights Across Key National Markets

The United States is focused on obesity and diabetes treatment access, coverage policy, safety, and supply continuity. Canada’s priorities include public and private reimbursement variation and provincial care pathways. Mexico and Brazil are balancing growing cardiometabolic needs with affordability and uneven access. The United Kingdom emphasizes national guidance, structured obesity services, and resource prioritization. France, Germany, Italy, and Spain operate within European regulatory frameworks but differ in reimbursement, prescribing, and service organization. China is expanding diabetes and obesity management amid evolving regulation and urban-rural access differences. Japan and South Korea emphasize aging populations, metabolic disease management, and careful clinical integration. India faces a large diabetes burden alongside pronounced variation in affordability, diagnosis, and healthcare delivery. Australia combines established clinical systems with geographically uneven access. Russia’s care environment is shaped by domestic availability, regulatory conditions, and healthcare-system resilience.

Actionable Priorities for Industry and Healthcare Leaders

Leaders should prioritize evidence-based patient selection, clear education on administration and expected effects, and structured follow-up for tolerability, adherence, and clinically meaningful outcomes. Access strategies should account for reimbursement rules, affordability, vulnerable populations, and continuity of supply rather than relying on demand alone. Organizations should strengthen pharmacovigilance, counterfeit-risk controls, and responsible communications that distinguish approved indications from unsupported use. Partnerships with clinicians, payers, regulators, and patient groups can improve pathway design. AI investments should begin with narrowly defined, validated use cases and include bias testing, cybersecurity, auditability, and clinician accountability.

Research Methodology for the Executive Summary

This executive summary uses the supplied market definition-glucagon-like peptide-1 agonists-and organizes findings across the required regions, groups, and countries. The analysis applies a qualitative synthesis of established clinical, regulatory, access, and health-system considerations relevant to GLP-1 agonist use. It deliberately excludes market estimates, market sizing, market shares, forecasts, and company-specific discussion. Regional and national observations are framed as contextual patterns rather than uniform conditions, because indications, reimbursement, clinical guidance, supply, and regulatory requirements vary by jurisdiction.

Conclusion: Building Responsible GLP-1 Agonist Access

GLP-1 agonists are contributing to a broader transformation in diabetes and obesity care, linking glycemic management with weight and cardiometabolic risk. Their benefits will depend not only on clinical efficacy, but also on appropriate prescribing, sustained monitoring, affordability, reliable supply, and fair access. Regional and country differences make adaptable implementation essential. Health-system leaders that combine rigorous evidence, patient-centered services, responsible digital tools, and strong safety governance will be better positioned to realize therapeutic value while managing practical and ethical risks.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Glucagon Like Peptide-1 Agonists Market, by Product
7.1. Introduction
7.2. Dulaglutide
7.3. Exenatide
7.4. Liraglutide
7.5. Semaglutide
8. Glucagon Like Peptide-1 Agonists Market, by Indication
8.1. Introduction
8.2. Obesity
8.3. Type 2 Diabetes
9. Glucagon Like Peptide-1 Agonists Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Subcutaneous
10. Glucagon Like Peptide-1 Agonists Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Glucagon Like Peptide-1 Agonists Market, by End User
11.1. Introduction
11.2. Clinic
11.3. Homecare
11.4. Hospital
12. Glucagon Like Peptide-1 Agonists Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Glucagon Like Peptide-1 Agonists Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Glucagon Like Peptide-1 Agonists Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Amgen
16.2. AstraZeneca
16.3. Boehringer Ingelheim
16.4. Dr. Reddy’s Laboratories
16.5. Eli Lilly and Company
16.6. Novo Nordisk
16.7. Pfizer
16.8. Roche
16.9. Sanofi
16.10. Sun Pharmaceutical Industries
16.11. Viking Therapeutics
16.12. Zealand Pharma
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Glucagon Like Peptide-1 Agonists Market, Years Considered for the Study
FIGURE 2. Global Glucagon Like Peptide-1 Agonists Market, Research Design
FIGURE 3. Global Glucagon Like Peptide-1 Agonists Market, Research Framework
FIGURE 4. Global Glucagon Like Peptide-1 Agonists Market, Data Triangulation
FIGURE 5. Global Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Glucagon Like Peptide-1 Agonists Market Size, by Product, 2025 vs 2032 (%)
FIGURE 7. Global Glucagon Like Peptide-1 Agonists Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Glucagon Like Peptide-1 Agonists Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Glucagon Like Peptide-1 Agonists Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Glucagon Like Peptide-1 Agonists Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Glucagon Like Peptide-1 Agonists Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Glucagon Like Peptide-1 Agonists Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Glucagon Like Peptide-1 Agonists Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Glucagon Like Peptide-1 Agonists Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Glucagon Like Peptide-1 Agonists Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Glucagon Like Peptide-1 Agonists Market Segmentation & Coverage
TABLE 2. Global Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 3. Global Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 4. Global Dulaglutide Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Dulaglutide Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Dulaglutide Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Exenatide Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Exenatide Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Exenatide Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Liraglutide Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Liraglutide Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Liraglutide Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Semaglutide Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Semaglutide Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Semaglutide Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 17. Global Obesity Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Obesity Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Obesity Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Type 2 Diabetes Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Type 2 Diabetes Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Type 2 Diabetes Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 24. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 31. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 41. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Homecare Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Homecare Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Homecare Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Glucagon Like Peptide-1 Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Glucagon Like Peptide-1 Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 57. North America Glucagon Like Peptide-1 Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. North America Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 59. North America Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 60. North America Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 61. North America Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 62. North America Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 63. Latin America Glucagon Like Peptide-1 Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Latin America Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 65. Latin America Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 66. Latin America Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 67. Latin America Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 68. Latin America Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 69. Europe Glucagon Like Peptide-1 Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Europe Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 71. Europe Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 72. Europe Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 73. Europe Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. Europe Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. Middle East Glucagon Like Peptide-1 Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Middle East Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 77. Middle East Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 78. Middle East Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 79. Middle East Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. Middle East Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Africa Glucagon Like Peptide-1 Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Africa Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 83. Africa Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 84. Africa Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 85. Africa Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. Africa Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Global Glucagon Like Peptide-1 Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. ASEAN Glucagon Like Peptide-1 Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. ASEAN Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 90. ASEAN Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 91. ASEAN Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 92. ASEAN Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. ASEAN Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. GCC Glucagon Like Peptide-1 Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. GCC Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 96. GCC Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 97. GCC Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 98. GCC Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. GCC Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 100. European Union Glucagon Like Peptide-1 Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. European Union Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 102. European Union Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 103. European Union Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 104. European Union Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. European Union Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 106. BRICS Glucagon Like Peptide-1 Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. BRICS Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 108. BRICS Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 109. BRICS Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 110. BRICS Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. BRICS Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. G7 Glucagon Like Peptide-1 Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. G7 Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 114. G7 Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 115. G7 Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 116. G7 Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. G7 Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. NATO Glucagon Like Peptide-1 Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. NATO Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 120. NATO Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 121. NATO Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 122. NATO Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. NATO Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. Global Glucagon Like Peptide-1 Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. United States Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 126. United States Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 127. United States Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 128. United States Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 129. United States Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 130. United States Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. Canada Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 132. Canada Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 133. Canada Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. Canada Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 135. Canada Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. Canada Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. Mexico Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 138. Mexico Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 139. Mexico Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 140. Mexico Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 141. Mexico Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. Mexico Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. Brazil Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 144. Brazil Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 145. Brazil Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 146. Brazil Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 147. Brazil Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. Brazil Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 149. United Kingdom Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 150. United Kingdom Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 151. United Kingdom Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 152. United Kingdom Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 153. United Kingdom Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. United Kingdom Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. Germany Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 156. Germany Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 157. Germany Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. Germany Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 159. Germany Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Germany Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 161. France Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 162. France Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 163. France Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 164. France Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 165. France Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. France Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Russia Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 168. Russia Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 169. Russia Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. Russia Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. Russia Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 172. Russia Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. Italy Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 174. Italy Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 175. Italy Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 176. Italy Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 177. Italy Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. Italy Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. Spain Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 180. Spain Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 181. Spain Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 182. Spain Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 183. Spain Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. Spain Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. China Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 186. China Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 187. China Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. China Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 189. China Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. China Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. India Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 192. India Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 193. India Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 194. India Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 195. India Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. India Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. Japan Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 198. Japan Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 199. Japan Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 200. Japan Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 201. Japan Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. Japan Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Australia Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 204. Australia Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 205. Australia Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 206. Australia Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. Australia Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. Australia Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. South Korea Glucagon Like Peptide-1 Agonists Market Size, 2017-2032 (USD Million)
TABLE 210. South Korea Glucagon Like Peptide-1 Agonists Market Size, by Product, 2017-2032 (USD Million)
TABLE 211. South Korea Glucagon Like Peptide-1 Agonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 212. South Korea Glucagon Like Peptide-1 Agonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 213. South Korea Glucagon Like Peptide-1 Agonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. South Korea Glucagon Like Peptide-1 Agonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. Global Glucagon Like Peptide-1 Agonists Market Share, by Key Player, 2025
TABLE 216. Global Glucagon Like Peptide-1 Agonists Market, Key Experts

Companies Mentioned

  • Amgen
  • AstraZeneca
  • Boehringer Ingelheim
  • Dr. Reddy’s Laboratories
  • Eli Lilly and Company
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi
  • Sun Pharmaceutical Industries
  • Viking Therapeutics
  • Zealand Pharma

Related Topics

Related Reports

Glucagon-Like Peptide-1 (GLP-1) Agonists - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036 - Product Image

Glucagon-Like Peptide-1 (GLP-1) Agonists - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036

  • Report
  • 120 Pages
  • Global
From
Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Global Report 2026 - Product Image

Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Market Global Report 2026

  • Report
  • 250 Pages
  • Global
From
Glucagon-Like Peptide 1 Agonists Market - Global Strategic Business Report - Product Image

Glucagon-Like Peptide 1 Agonists Market - Global Strategic Business Report

  • Report
  • 375 Pages
  • Global
From
Glucagon-like Peptide-1 Agonists Market Outlook 2026-2034: Market Share, and Growth Analysis by Molecule (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Semaglutide, Tirzepatide, Others), Route of Administration, Indication - Product Image

Glucagon-like Peptide-1 Agonists Market Outlook 2026-2034: Market Share, and Growth Analysis by Molecule (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Semaglutide, Tirzepatide, Others), Route of Administration, Indication

  • Report
  • 160 Pages
  • Global
From
Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Global Report 2026 - Product Image

Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Global Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Glucagon Like Peptide 1 Agonist Market

The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications. The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.